Products
Dinutuximab was approved in the United States and the EU in 2015 as a concentrate for the preparation of an infusion solution (Unituxin). It has not yet been registered in many countries.
Structure and properties
Dinutuximab is a chimeric monoclonal antibody (human/mouse).
Effects
Dinutuximab (ATC L01XC16) has cytotoxic properties. It binds to ganglioside GD2, which is expressed primarily on the surface of neuroblastoma cells. The binding elicits a cell-toxic response from the immune system.
Indications
For the treatment of high-risk neuroblastoma.
Dosage
According to the SmPC. The drug is administered as an intravenous infusion.
Adverse effects
The most common possible adverse effects include hypotension, pain, hypersensitivity, fever, and hives.
